@misc{indiciae2bad98f76f4f,
  title = {Safety, tolerability, and efficacy of RIPK1 inhibitor, SAR443820, in amyotrophic lateral sclerosis (HIMALAYA): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.},
  author = {Merit E Cudkowicz and Jeremy Shefner and Leonard H van den Berg and Adriano Chio and Dongsheng Fan and Julian Gro\&\#xdf;kreutz and Christian Lunetta and Richard M Tsai and Ye Li and Erik Wallstroem and Li Xiong and Yixin Chen and Nazem Atassi and HIMALAYA Phase 2 Study Group},
  year = {2026},
  doi = {10.1016/s1474-4422(26)00277-2},
  url = {https://pubmed.ncbi.nlm.nih.gov/42716044/},
  note = {Source identifier: 42716044}
}